Inactive/Delisted stock

Eliem Therapeutics Stock (NASDAQ:ELYM)

Forecast Ownership Financials Chart

Previous Close

$5.16

52W Range

$2.35 - $11.55

50D Avg

$6.46

200D Avg

$5.57

Market Cap

$342.68M

Avg Vol (3M)

$519.72K

Beta

-0.38

Div Yield

ELYM Company Profile

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Aug 10, 2021

Website

ELYM Performance

ELYM Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-40.27M	$-45.13M	$-35.67M
Net Income	$-35.12M	$-45.35M	$-47.48M
EBITDA	$-40.27M	$-43.65M	$-35.50M
Basic EPS	$-1.30	$-1.72	$-3.87
Diluted EPS	$-1.30	$-1.72	$-3.87

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
IPSC	Century Therapeutics, Inc.
ACRV	Acrivon Therapeutics, Inc. Common Stock
ANEB	Anebulo Pharmaceuticals, Inc.
HCWB	HCW Biologics Inc.
CSBR	Champions Oncology, Inc.
MNOV	MediciNova, Inc.
PHVS	Pharvaris N.V.
RZLT	Rezolute, Inc.
ADAG	Adagene Inc.
MOLN	Molecular Partners AG
PMVP	PMV Pharmaceuticals, Inc.
AVTE	Aerovate Therapeutics, Inc.
ANTX	AN2 Therapeutics, Inc.
PEPG	PepGen Inc.
STTK	Shattuck Labs, Inc.